Expert Insights on Pharmacy Benefits

A nationwide financial institution with 4,800 covered lives achieved dramatic cost savings by partnering with Innovative Rx Strategies to optimize their pharmacy benefits.

Learn how annual market checks help self-funded employers benchmark PBM pricing, validate contract performance and uncover savings — without a full RFP.

A regional employee benefit trust serving approximately 1,000 members had partnered with a major national health insurer and one of the nation’s largest pharmacy benefit managers (PBMs) to provide pharmacy benefits for more than 30 years.

Biosimilars are cutting some costs, but newer anti-inflammatory biologics are driving specialty spend higher. See what employers need to know for 2027 planning.

Health care legislation is always changing, from prescription drug coverage to transparency requirements and PBM regulation. So, what should self-funded employers know?

The complexity of pharmacy benefits manager (PBM) contracts can make it difficult for employers to know exactly where their plan dollars are going and whether their PBM is delivering the full value promised in the contract.

Specialty medications continue to reshape pharmacy benefit costs, even as GLP-1s dominate much of the conversation. Immunology and oncology remain among the highest-cost drug categories for plan sponsors, driven by new therapies with six-figure annual price tags, rising inflammatory drug …

It’s stop-loss insurance renewal season, and for self-funded employers, the stakes can be high with regard to the impact on health care costs for the upcoming plan year. The decisions employers make throughout the plan year influence their position when …

The recent launch of generic versions of Xeljanz is a striking example of the savings that can be generated when competitive drugs enter the market.

Discover key takeaways from a standout SHRM26 session on remote work, including how to design more engaging, interactive, and human virtual experiences.

As a leading pharmacy benefits consultant, Innovative Rx Strategies continuously monitors emerging trends and priorities across the industry. In our latest survey, we found that financial institutions were overrepresented in the conversations that followed.

GLP‑1 medications have moved far beyond diabetes management—reshaping obesity care, pharmacy practice, and the broader healthcare marketplace. But with rapid innovation comes increasing complexity, regulatory scrutiny, and clinical risk.